- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Examining Axatilimab in the AGAVE-201 Trial For cGVHD
Sergio A. Giralt, MD, discusses how the mechanism of action of axatilimab, recently approved by the FDA for chronic graft-vs-host disease (cGVHD), involves targeting CSF1R to disrupt macrophage differentiation and reduce inflammation, and how the AGAVE-201 trial demonstrated strong efficacy and safety, which will influence clinical decision-making and potentially change the GVHD treatment landscape by offering a novel therapeutic option.
Video content above is prompted by the following:
- What did this abstract elucidate about the mechanism of action of axatilimab, which was approved by the FDA this year as a treatment for chronic graft-vs-host disease (cGVHD)?
- How will this abstract affect your clinical decision-making?
- The AGAVE-201 trial led to the approval of axatilimab for cGVHD. Discuss the methods and study design of this trial.
- What were the key efficacy and safety data seen in the AGAVE-201 trial with axatilimab?
- How do these results influence your clinical practice?
- How do you see the GVHD treatment landscape changing with the introduction of axatilimab?
ICYMI: Highlights From AMCP Nexus 2024
December 26th 2024Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.
Read More
